Michael Lahn

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.

Iñaki F Trocóniz, Sophie Glatt, J. Yingling, 2008, European journal of cancer.

Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

Ute Wirkner, Peter Peschke, Peter E Huber, 2011, Neoplasia.

Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFβR therapy

Thomas Zander, Joachim L Schultze, Daniela Eggle, 2010, Pharmacogenetics and genomics.